Enosim Bio-tech Co., Ltd
Update：2026/11/10
Industries
Main Industry
Health Care
Main Product/Service
Breath-Care
Enosim developed the ASTRON, a real-time monitoring and identification breath analysis system for Ventilator-Associated Pneumonia (VAP).
Ventilator-associated pneumonia refers to a bacterial lung infection in intensive care units(ICU), and the patients have been treated with a respirator for more than 48 hours. VAP is the most common nosocomial infection in ICU, and the rate of infection is about 7 to 14%. The mortality rate can reach from 35 to 90%. According to the US study, the additional medical expenses is about US$ 40,000 (about NT$1,280,000). The current species diagnosis relies on the experience of clinical physicians . And the sputum culture to identify bacterium can only get the sucess rate about 60% after 3 to 5 days.
In ICU, there is a umment medical need for the rapid VAP identification. In Taiwan, the number of people in the ICU has increased by 2.4 times in past ten years. However, the patient who leaving rate from respiratory is only 70%, the rate of demanding is reached 142%. The cost as reached NT$4.2 billion.
Enosim developed the ASTRON, a real-time monitoring and identification breath analysis system for Ventilator-Associated Pneumonia (VAP).
Ventilator-associated pneumonia refers to a bacterial lung infection in intensive care units(ICU), and the patients have been treated with a respirator for more than 48 hours. VAP is the most common nosocomial infection in ICU, and the rate of infection is about 7 to 14%. The mortality rate can reach from 35 to 90%. According to the US study, the additional medical expenses is about US$ 40,000 (about NT$1,280,000). The current species diagnosis relies on the experience of clinical physicians . And the sputum culture to identify bacterium can only get the sucess rate about 60% after 3 to 5 days.
In ICU, there is a umment medical need for the rapid VAP identification. In Taiwan, the number of people in the ICU has increased by 2.4 times in past ten years. However, the patient who leaving rate from respiratory is only 70%, the rate of demanding is reached 142%. The cost as reached NT$4.2 billion.
The content above was translated by Ai
Founded Year
2017
Unified Business No.
56623612
Status
Active
Number of Employees
0
Total Paid-in
Capital
12,565,000 (NT$)
Location of Company
Taiwan
, Hsinchu City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Enosim Bio-tech develops AI-enabled digital olfaction and electronic nose systems, integrating sensor hardware, edge AI, and cloud-based OdorOps analytics for real-time chemical detection. Applications span industrial inspection, environmental monitoring, food quality, and medical breath analysis — enabling devices and robots to "smell" within IoT and smart infrastructure environments.
The content above was translated by Ai
